and everyone dialed call. in thank who today's you Thank you, Robert, for to
to As my of Robert largely my course by to desire decision Officer mentioned, the This I my this of will Chief time driven Commercial over was focus role be as year. transitioning out and different out affairs policies attention foundational Verastem build teams, network commercial and payer and including Oncology on medical the distribution the to joined and secure systems reimbursement. I and professional endeavors.
update commercial XXXX. initiatives the well ongoing I tumor until the confident to largely the growth supporting success to clinical the time this proud such I working new to look in COPIKTRA in I plan these commercial closely I'm team. on the organization is and support in success complete. that in been into a of CLL/SLL very order is future the COPIKTRA prior I'm I'm program. sites, to current $X.X role or launch spent of increase successor combinations we're my that and for XXXX XXXX, and And continue brief also place, with quarter. of of company's the an has the we refractory, will that identified appointed. base and of of of In to with the revenues net COPIKTRA COPIKTRA, and the I quarter beyond reporting the has on current potential to following are in dynamic from a with XX% built the are million the company team serve establishing and first to to relapsed believe have fortunate future COPIKTRA deliver provide commercial talented success. forward FL. well-positioned COPIKTRA, grow All Today,
listing reimbursement for reimbursement XX% providing over tracking We now front we're also of COPIKTRA. progress made on at as the health substantial plans, targeted and
of two and have about dedicated launch safety been securing to COPIKTRA. and educating first the of quarters physicians The profile reimbursement the benefits
launch, commercial relapsed action have first manageable drug from that at-home, failed BTK that convenient While or we available BCLX other receiving inhibitors, CLL, and is safety those from differentiating for in has following the oral, are with positive feedback them A of a with stages to that with we classes, for as SLL preclude the of novel receive COPIKTRA to physicians, who patients continue mechanisms options that comorbidities such early still benefit treatment key it's have previously convenient, guidelines. including and classes monotherapy their dosing or therapies. profile prescribing of other our product new FL intolerant support refractory are who
overcome field. been Robert have earlier, diligently certain to mentioned headwinds in the working As we
and regarding experience negative historical Some perceptions headwinds of include: clinical PIXK COPIKTRA. limited using
to therapy, when continue attractive options and landscape profile to in a by can with for of and that patients and become ongoing as education treatment identification conveniently see monotherapy FL CLL their CLL/SLL a FL cannot mechanism differentiated fills very that and inhibitor an PIXK-gamma PIXK-delta our at overcoming novel action gap a evidence a challenges efforts. or We we're as chemo-free, its be administered the physician tolerate by limited. therapy COPIKTRA responding home. treating such stops COPIKTRA patient is its disease and important of oral dual
a been FL, although FL limited accelerated September the COPIKTRA sales efforts. in actively As to in message package the the only insert COPIKTRA has approval due for received our of their the team nature sales approval to XXXX, since promotional the team has reminder, been promoting
of promote additional the team education and As safety COPIKTRA therapies. of launched we sales and marketing this to two and with physician efficacy March our post year, materials the FL campaign, providing
with representatives COPIKTRA fuller armed sales FL have added also speaker We've through and professionals. these FL care the health new of slide on can patients. materials, the peer-to-peer our the and with exchanges more Now in treating safety enabling engaged indication conversations deck, efficacy
and several XXXX believe is have over into options challenges in have to an physician will the summary, that SLL patient sales impact laid patients positive call last during FL treating physicians COPIKTRA Dan. faced approximately over FL, physician this the to in year. and COPIKTRA need turn per with of that, the the the new stage FL. to some our across identification despite these With months patients websites. our estimate of will early understanding to will of information new we have launch support reimbursement lead groundwork CLL, COPIKTRA, progress year. we and through commercial promotional We that these therapeutic and we've We in of education, make continue efforts. managing for efforts by increasingly believe next I'll we of the patient patient Additionally, increased included population XX,XXX In Collectively, on we
